Last week, the GENEGUT consortium, where CarboHyde is a full partner, gathered for the project’s 3rd General Assembly meeting. This time again in-person, hosted by CarboHyde in Budapest, Hungary. The two-day meeting was a great opportunity to discuss the significant progress of GENEGUT’s first year and prepare for the next steps towards the development of an RNA-based therapy for Crohn’s Disease.
Just over 30 attendees from all 9 GENEGUT partners got together to hold this General Assembly meeting. Joined also by one of the project’s Scientific Advisory Board (SAB) members, Prof. Katie Whitehead (CMU). Prof. Dr. Csóka Ildikó from the University of Szeged, Hungary joined also as a guest lecturer and held an interesting session focusing on regulatory basics for nucleic acid APIs.
After kicking-off the day with a team-building activity, day one was dedicated to updates from the management side of the project and all its scientific work packages. The WP leads and early-career researchers presented their progress, interaction with other WPs, challenges and next steps. “I think we have made significant progress over our first year and I am confident we can build on this over the coming months.” – concluded GENEGUT coordinator Prof. Caitriona O’Driscoll (UCC).
CarboHyde’s main responsibility in the project is to create a library of cyclodextrin-based compounds. Our colleague, Milo Malanga presented the progress CarboHyde’s team has achieved in the past year along the main results as well as the challenges this work involved.
Besides the focused work this workshop required from all the participants, we had the opportunity to visit some of the main attractions of Budapest, such as the Parliament and the Kossuth square and also enjoyed the local cousine.
GENEGUT meets for 3rd General Assembly
